HUP0201122A2 - Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them - Google Patents
Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- HUP0201122A2 HUP0201122A2 HU0201122A HUP0201122A HUP0201122A2 HU P0201122 A2 HUP0201122 A2 HU P0201122A2 HU 0201122 A HU0201122 A HU 0201122A HU P0201122 A HUP0201122 A HU P0201122A HU P0201122 A2 HUP0201122 A2 HU P0201122A2
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- pyrimidinone compounds
- pyrimidinone
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9910048A GB9910048D0 (en) | 1999-05-01 | 1999-05-01 | Novel compounds |
GB0002096A GB0002096D0 (en) | 2000-01-28 | 2000-01-28 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0201122A2 true HUP0201122A2 (en) | 2002-08-28 |
HUP0201122A3 HUP0201122A3 (en) | 2003-11-28 |
Family
ID=26243514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0201122A HUP0201122A3 (en) | 1999-05-01 | 2000-04-25 | Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them |
Country Status (29)
Country | Link |
---|---|
US (2) | US6953803B1 (hu) |
EP (2) | EP1479671B1 (hu) |
JP (1) | JP2002543190A (hu) |
KR (1) | KR20020012200A (hu) |
CN (1) | CN1286822C (hu) |
AR (1) | AR023777A1 (hu) |
AT (2) | ATE283845T1 (hu) |
AU (1) | AU766003B2 (hu) |
BR (1) | BR0010220A (hu) |
CA (1) | CA2371671A1 (hu) |
CO (1) | CO5170521A1 (hu) |
CZ (1) | CZ20013904A3 (hu) |
DE (2) | DE60042286D1 (hu) |
DK (1) | DK1175408T3 (hu) |
ES (1) | ES2233361T3 (hu) |
HK (1) | HK1044757B (hu) |
HU (1) | HUP0201122A3 (hu) |
IL (1) | IL146210A0 (hu) |
MX (1) | MXPA01011186A (hu) |
MY (1) | MY136037A (hu) |
NO (1) | NO20015329D0 (hu) |
NZ (1) | NZ515137A (hu) |
PE (1) | PE20010070A1 (hu) |
PL (1) | PL351690A1 (hu) |
PT (1) | PT1175408E (hu) |
SI (1) | SI1175408T1 (hu) |
TR (1) | TR200103216T2 (hu) |
UY (1) | UY26132A1 (hu) |
WO (1) | WO2000066567A1 (hu) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002543190A (ja) * | 1999-05-01 | 2002-12-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | ピリミジノン化合物 |
WO2001060805A1 (en) * | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
CA2530816A1 (en) * | 2003-07-02 | 2005-01-13 | Bayer Healthcare Ag | Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
US20070166777A1 (en) | 2004-04-16 | 2007-07-19 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
DE102004061006A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Benzylthio-1,2,4-triazin-5(2H)-one |
DE102004061009A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
CN1954826A (zh) * | 2005-10-26 | 2007-05-02 | 上海生物芯片有限公司 | 银杏叶提取物在降低胆固醇方面的用途 |
JP5437996B2 (ja) | 2007-05-11 | 2014-03-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 皮膚潰瘍の治療方法 |
MX2009012188A (es) | 2007-05-11 | 2010-02-24 | Univ Jefferson | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. |
AR081399A1 (es) | 2010-05-17 | 2012-08-29 | Glaxo Group Ltd | Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos. |
JP5886310B2 (ja) * | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドGlaxo Group Limited | Lp−PLA2により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
WO2013000108A1 (zh) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
RU2014107486A (ru) | 2011-07-27 | 2015-09-10 | Глэксо Груп Лимитед | Бициклические пиримидоновые соединения |
RU2014107484A (ru) | 2011-07-27 | 2015-09-10 | Глэксо Груп Лимитед | ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2 |
WO2013068875A1 (en) * | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
CN105008365B (zh) | 2013-01-25 | 2017-03-15 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
WO2014114249A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
EP2948452B1 (en) | 2013-01-25 | 2017-08-09 | GlaxoSmithKline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
US9552473B2 (en) | 2014-05-14 | 2017-01-24 | Microsoft Technology Licensing, Llc | Claiming data from a virtual whiteboard |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
CN106008362B (zh) * | 2016-05-24 | 2018-08-10 | 杰达维(上海)医药科技发展有限公司 | 一种嘧啶衍生物的制备方法 |
JP6545747B2 (ja) * | 2017-05-09 | 2019-07-17 | 山田化学工業株式会社 | 色素化合物 |
AU2020379796C1 (en) | 2019-11-09 | 2024-05-02 | Shanghai SIMR Biotechnology Co., Ltd | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1582527A (en) * | 1975-12-29 | 1981-01-07 | Smith Kline French Lab | Pyrimidone and thiopyrimidone derivatives |
US6417192B1 (en) * | 1997-11-06 | 2002-07-09 | Smithkline Beecham P.L.C. | Pyrimidinone compounds and pharmaceutical compositions containing them |
EP1105377B1 (en) * | 1998-08-21 | 2003-10-08 | SmithKline Beecham plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
JP2002543190A (ja) * | 1999-05-01 | 2002-12-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | ピリミジノン化合物 |
-
2000
- 2000-04-25 JP JP2000615598A patent/JP2002543190A/ja active Pending
- 2000-04-25 PT PT00920741T patent/PT1175408E/pt unknown
- 2000-04-25 MX MXPA01011186A patent/MXPA01011186A/es active IP Right Grant
- 2000-04-25 SI SI200030609T patent/SI1175408T1/xx unknown
- 2000-04-25 TR TR2001/03216T patent/TR200103216T2/xx unknown
- 2000-04-25 AT AT00920741T patent/ATE283845T1/de active
- 2000-04-25 DK DK00920741T patent/DK1175408T3/da active
- 2000-04-25 CA CA002371671A patent/CA2371671A1/en not_active Abandoned
- 2000-04-25 AT AT04077397T patent/ATE432265T1/de not_active IP Right Cessation
- 2000-04-25 CZ CZ20013904A patent/CZ20013904A3/cs unknown
- 2000-04-25 DE DE60042286T patent/DE60042286D1/de not_active Expired - Fee Related
- 2000-04-25 ES ES00920741T patent/ES2233361T3/es not_active Expired - Lifetime
- 2000-04-25 US US10/030,661 patent/US6953803B1/en not_active Expired - Lifetime
- 2000-04-25 KR KR1020017013976A patent/KR20020012200A/ko not_active Application Discontinuation
- 2000-04-25 IL IL14621000A patent/IL146210A0/xx unknown
- 2000-04-25 CN CNB008094918A patent/CN1286822C/zh not_active Expired - Lifetime
- 2000-04-25 EP EP04077397A patent/EP1479671B1/en not_active Expired - Lifetime
- 2000-04-25 NZ NZ515137A patent/NZ515137A/en unknown
- 2000-04-25 HU HU0201122A patent/HUP0201122A3/hu unknown
- 2000-04-25 WO PCT/EP2000/003727 patent/WO2000066567A1/en not_active Application Discontinuation
- 2000-04-25 BR BR0010220-2A patent/BR0010220A/pt not_active IP Right Cessation
- 2000-04-25 EP EP00920741A patent/EP1175408B1/en not_active Expired - Lifetime
- 2000-04-25 AU AU41203/00A patent/AU766003B2/en not_active Expired
- 2000-04-25 PL PL00351690A patent/PL351690A1/xx not_active Application Discontinuation
- 2000-04-25 DE DE60016397T patent/DE60016397T2/de not_active Expired - Lifetime
- 2000-04-27 AR ARP000102001A patent/AR023777A1/es not_active Application Discontinuation
- 2000-04-28 CO CO00030779A patent/CO5170521A1/es not_active Application Discontinuation
- 2000-04-28 UY UY26132A patent/UY26132A1/es not_active Application Discontinuation
- 2000-04-28 MY MYPI20001870A patent/MY136037A/en unknown
- 2000-04-28 PE PE2000000399A patent/PE20010070A1/es not_active Application Discontinuation
-
2001
- 2001-10-31 NO NO20015329A patent/NO20015329D0/no not_active Application Discontinuation
-
2002
- 2002-06-20 HK HK02104602.0A patent/HK1044757B/zh not_active IP Right Cessation
-
2004
- 2004-02-11 US US10/776,876 patent/US7115616B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0201122A3 (en) | Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0203136A3 (en) | Piperazine compounds, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203316A3 (en) | Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0204245A3 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0201376A2 (en) | Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds | |
HUP0300618A3 (en) | Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
HUP0203107A3 (en) | Novel spiro compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0105114A3 (en) | Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation | |
HUP0203183A3 (en) | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP0203548A3 (en) | New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203294A3 (en) | Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0200396A3 (en) | Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203052A3 (en) | Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0201516A2 (en) | 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0105108A3 (en) | Amide compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0201753A2 (en) | Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0201206A2 (en) | Antibacterial compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0201402A3 (en) | Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them | |
HUP0203385A3 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203140A3 (en) | Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0202075A3 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203184A3 (en) | Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0202731A3 (en) | O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
HK1039122A1 (zh) | 取代的6-苄基-4-氧代嘧啶,其製備方法以及含該化合物的藥物組合物 | |
HUP0100489A3 (en) | New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |